Brazilian scientists have announced a breakthrough in antiviral research, demonstrating that high-frequency ultrasound waves can destroy SARS-CoV-2 and influenza viruses without harming human cells. The findings, published in the peer-reviewed journal Scientific Reports, reveal that targeted acoustic resonance causes structural damage to viral particles, leading to their complete inactivation although leaving surrounding tissue unharmed.
The study, conducted by researchers at the University of São Paulo (USP) and supported by the São Paulo Research Foundation (FAPESP), builds on prior investigations into the therapeutic potential of ultrasound in medical applications. According to the research team, the technique exploits the physical properties of viral envelopes, using sound energy to induce mechanical stress that compromises the integrity of the pathogen’s outer membrane.
Lead researcher Odemir Martinez Bruno, a professor at USP’s Institute of Physics, explained in interviews with Brazilian media that the effect resembles how popcorn kernels burst when heated — only in this case, the energy comes from mechanical vibrations rather than thermal energy. “We tested that the energy from sound waves causes a morphological change in viral particles until they reach the point of explosion,” Bruno stated, as reported by FAPESP in its official press release dated April 17, 2026.
The method specifically employed ultrasound frequencies similar to those used in routine diagnostic imaging, such as echocardiograms or fetal ultrasounds, suggesting a potentially low barrier to clinical adaptation if further safety and efficacy studies confirm the results. Researchers emphasized that the treatment does not rely on heat or chemical agents, reducing the risk of cytotoxicity or inflammatory responses in treated tissues.
Beyond SARS-CoV-2 and H1N1 influenza, the research team indicated that the approach could be extended to other enveloped viruses, including dengue, Zika and chikungunya — all of which pose significant public health challenges in tropical and subtropical regions. These viruses share structural similarities in their lipid membranes, making them theoretically susceptible to similar mechanical disruption via resonance.
Independent verification of the study’s publication confirms its appearance in Scientific Reports, an open-access journal published by Nature Portfolio, with the article titled “Ultrasound-induced inactivation of SARS-CoV-2 and influenza A virus via acoustic resonance” made available online on April 16, 2026. The paper details experimental procedures involving controlled exposure of viral samples to ultrasound waves in vitro, followed by assessment of viral integrity using electron microscopy and infectivity assays.
While the results are promising, experts caution that the findings represent an early-stage laboratory proof of concept. Translation to human applications would require extensive preclinical testing in animal models, followed by phased clinical trials to evaluate delivery methods, dosage, long-term safety, and effectiveness in complex biological environments such as the respiratory tract or bloodstream.
No human trials have been announced as of April 2026, and the research team has not disclosed plans for commercial development or partnerships with medical device manufacturers. FAPESP, which funded the study through its regular grant program, noted that the operate aligns with broader efforts to explore non-pharmacological interventions against infectious diseases, particularly in resource-limited settings where access to antivirals or vaccines may be constrained.
The announcement comes amid continued global interest in innovative approaches to managing respiratory infections, especially as seasonal influenza and emerging variants of SARS-CoV-2 continue to challenge public health systems. While vaccination and monoclonal antibodies remain central to prevention and treatment strategies, adjunctive methods that can reduce viral load or inhibit transmission are actively being explored.
For now, the Brazilian team’s work contributes to a growing body of research into physical methods of virus inactivation, joining other investigational techniques such as ultraviolet C (UVC) light, pulsed electric fields, and nanoparticle-based traps. Unlike some of these approaches, ultrasound offers the advantage of deep tissue penetration and established safety profiles in medical imaging, potentially enabling targeted applications in organs like the lungs or liver.
As with all early-stage discoveries, the path from laboratory observation to real-world impact remains uncertain. Still, the study underscores the value of interdisciplinary research — combining physics, virology, and biomedical engineering — in uncovering novel ways to combat infectious threats. Further updates will depend on whether the research team publishes follow-up studies or secures additional funding for preclinical development.
Readers interested in tracking the progress of this research can consult the USP Institute of Physics website or FAPESP’s public database of funded projects for official updates. Peer-reviewed journals such as Scientific Reports, Ultrasound in Medicine & Biology, and Antiviral Research are likely venues for future publications on this topic.
We invite our global audience to share thoughts and questions in the comments below. What potential applications do you see for non-invasive antiviral technologies like ultrasound? How should safety and accessibility be balanced as such innovations move toward clinical employ?
Keep reading